The study examines the impact of tumor microenvironment (TME) characteristics on the efficacy of axi-cel (anti-CD19 CAR T cell therapy) versus standard of care (SOC) in second-line large B-cell lymphoma (LBCL). Key findings include: 1. **B Cell Gene Signature (GES) and CD19 Expression**: Both B cell GES and CD19 expression were significantly associated with improved event-free survival (EFS) for axi-cel but not for SOC. Axi-cel showed superior EFS over SOC regardless of B cell GES and CD19 expression. 2. **TME Immune Contexture**: Low CD19 expression in malignant cells correlated with a TME characterized by immune-suppressive stromal and myeloid genes, highlighting the inter-relation between malignant cell features and immune contexture. 3. **Tumor Burden and Prognostic Biomarkers**: Tumor burden, lactate dehydrogenase (LDH), and cell-of-origin impacted SOC more than axi-cel outcomes. T cell activation and B cell GES, which are associated with improved axi-cel outcome, decreased with increasing lines of therapy. 4. **Biomarkers and Treatment Resistance**: The study identified biomarkers associated with treatment resistance to axi-cel and SOC, providing insights into potential mechanisms of resistance. 5. **Product Characteristics**: Axi-cel products enriched in CCR7+CD45RA+ T cells, a stem-like phenotype, showed improved EFS in patients with lower CD19 protein expression and higher immunosuppressive features. 6. **Molecular Subgrouping**: Molecular subgrouping based on cell of origin did not impact outcomes for axi-cel, while it did for SOC, suggesting different mechanisms of action between the two therapies. 7. **TME Evolution**: The study observed a shift in influential biomarkers across lines of therapy, supporting earlier intervention with CAR T cell therapy. 8. **Clinical Implications**: The findings highlight the importance of understanding the TME in predicting response to CAR T cell therapy and suggest that axi-cel may be more effective in first-line therapy due to favorable tumor characteristics and T cell fitness. These results provide valuable insights into the mechanisms driving responsiveness to CAR T cell therapy and the potential for earlier intervention to improve outcomes in LBCL.The study examines the impact of tumor microenvironment (TME) characteristics on the efficacy of axi-cel (anti-CD19 CAR T cell therapy) versus standard of care (SOC) in second-line large B-cell lymphoma (LBCL). Key findings include: 1. **B Cell Gene Signature (GES) and CD19 Expression**: Both B cell GES and CD19 expression were significantly associated with improved event-free survival (EFS) for axi-cel but not for SOC. Axi-cel showed superior EFS over SOC regardless of B cell GES and CD19 expression. 2. **TME Immune Contexture**: Low CD19 expression in malignant cells correlated with a TME characterized by immune-suppressive stromal and myeloid genes, highlighting the inter-relation between malignant cell features and immune contexture. 3. **Tumor Burden and Prognostic Biomarkers**: Tumor burden, lactate dehydrogenase (LDH), and cell-of-origin impacted SOC more than axi-cel outcomes. T cell activation and B cell GES, which are associated with improved axi-cel outcome, decreased with increasing lines of therapy. 4. **Biomarkers and Treatment Resistance**: The study identified biomarkers associated with treatment resistance to axi-cel and SOC, providing insights into potential mechanisms of resistance. 5. **Product Characteristics**: Axi-cel products enriched in CCR7+CD45RA+ T cells, a stem-like phenotype, showed improved EFS in patients with lower CD19 protein expression and higher immunosuppressive features. 6. **Molecular Subgrouping**: Molecular subgrouping based on cell of origin did not impact outcomes for axi-cel, while it did for SOC, suggesting different mechanisms of action between the two therapies. 7. **TME Evolution**: The study observed a shift in influential biomarkers across lines of therapy, supporting earlier intervention with CAR T cell therapy. 8. **Clinical Implications**: The findings highlight the importance of understanding the TME in predicting response to CAR T cell therapy and suggest that axi-cel may be more effective in first-line therapy due to favorable tumor characteristics and T cell fitness. These results provide valuable insights into the mechanisms driving responsiveness to CAR T cell therapy and the potential for earlier intervention to improve outcomes in LBCL.